文献速递血栓与止血

ChAdOx1 nCoV-19疫苗诱导免疫性血栓性血小板减少症机制研究

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
PubMed 文献 · Blood · 2021-01-01

研究利用生物物理技术、小鼠模型和VITT患者样本,揭示ChAdOx1 nCoV-19疫苗诱导VITT的机制。疫苗组分与PF4形成抗原复合物,结合患者抗PF4抗体,并引发B细胞高亲和力抗体产生,激活血小板和中性粒细胞,促进血栓形成。

要点

  • 疫苗组分与PF4电荷驱动形成复合物,DNA可增强复合物形成
  • VITT患者抗PF4抗体高亲和力,依赖PF4或DNA激活血小板
  • 抗PF4抗体刺激中性粒细胞释放NETs,NETs在脑静脉血栓中丰富

核心结论

  • 疫苗诱导的PF4/腺病毒聚集体和促炎反应刺激病理性抗PF4抗体产生,驱动VITT血栓形成。

研究设计与样本

  • 使用生物物理技术、小鼠模型和VITT患者样本进行分析。

主要发现

  • 超分辨显微镜显示疫苗组分与PF4在血小板表面形成抗原复合物,VITT患者抗PF4抗体结合于此。
  • 蛋白质组学在含EDTA疫苗中鉴定出大量病毒生产来源的T-REx HEK293蛋白。
  • 注射疫苗增加小鼠血管渗漏,导致疫苗组分全身播散。
  • VITT患者抗PF4抗体在PF4或DNA及多聚磷酸聚阴离子存在下有效激活血小板。
  • 抗PF4抗体以血小板PF4依赖方式刺激中性粒细胞释放NETs,VITT患者血清中促凝NETs生物标志物升高,脑静脉血栓免疫组化显示大量NETs。

临床怎么用

  • VITT机制类似自身免疫性肝素诱导的血小板减少症,支持两步机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using biophysical techniques, mouse models, and analysis of VITT patient samples, we identified determinants of this vaccine-induced adverse reaction. Super-resolution microscopy visualized vaccine components forming antigenic complexes with platelet factor 4 (PF4) on platelet surfaces to which anti-PF4 antibodies obtained from VITT patients bound. PF4/vaccine complex formation was charge-driven and increased by addition of DNA. Proteomics identified substantial amounts of virus production-derived T-REx HEK293 proteins in the ethylenediaminetetraacetic acid (EDTA)-containing vaccine. Injected vaccine increased vascular leakage in mice, leading to systemic dissemination of vaccine components known to stimulate immune responses. Together, PF4/vaccine complex formation and the vaccine-stimulated proinflammatory milieu trigger a pronounced B-cell response that results in the formation of high-avidity anti-PF4 antibodies in VITT patients. The resulting high-titer anti-PF4 antibodies potently activated platelets in the presence of PF4 or DNA and polyphosphate polyanions. Anti-PF4 VITT patient antibodies also stimulated neutrophils to release neutrophil extracellular traps (NETs) in a platelet PF4-dependent manner. Biomarkers of procoagulant NETs were elevated in VITT patient serum, and NETs were visualized in abundance by immunohistochemistry in cerebral vein thrombi obtained from VITT patients. Together, vaccine-induced PF4/adenovirus aggregates and proinflammatory reactions stimulate pathologic anti-PF4 antibody production that drives thrombosis in VITT. The data support a 2-step mechanism underlying VITT that resembles the pathogenesis of (autoimmune) heparin-induced thrombocytopenia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021. PMID: 34587242. doi:10.1182/blood.2021013231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。